rabbit kcna2  (Alomone Labs)

Journal: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Article Title: Long Noncoding RNA Kcna2 Antisense RNA Contributes to Ventricular Arrhythmias via Silencing Kcna2 in Rats With Congestive Heart Failure

doi: 10.1161/JAHA.117.005965

Figure Lengend Snippet: Changes in Kcna2 antisense RNA (AS) and Kcna2 expression after congestive heart failure ( CHF ). A, Kcna2 AS levels were increased, and Kcna2 mRNA levels were reduced, in the hearts of rats with CHF (n=6). Control indicates sham surgery. B, Kcna2 protein levels were decreased in rat hearts with CHF (n=6). C, Quantitative real‐time RT‐ PCR results for Kcna2 AS and Kcna2 mRNA expression levels in phenylephrine‐induced cardiomyocyte hypertrophy (n=6). Control indicates untreated group; hypertrophy, treated with 50 μmol/L phenylephrine. D, Western blot showing Kcna2 expression levels in phenylephrine‐induced cardiomyocyte hypertrophy (n=6). * P <0.05 vs control, ** P <0.01 vs control, *** P <0.001 vs control.

Article Snippet: The following primary antibodies were used: anti‐rabbit Kcna2 (1:200; Alomone Labs), anti‐rabbit kvβ1 (1:1000; Abcam, Cambridge, UK), and anti‐GAPDH (1:1000; Cell Signaling Technology, Boston, MA) at 4°C overnight.

Techniques: Expressing, Control, Quantitative RT-PCR, Western Blot

Journal: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Article Title: Long Noncoding RNA Kcna2 Antisense RNA Contributes to Ventricular Arrhythmias via Silencing Kcna2 in Rats With Congestive Heart Failure

doi: 10.1161/JAHA.117.005965

Figure Lengend Snippet: The role of Kcna2 in regulating the decreased slow component of the delayed rectifier potassium current (I Ks ) and prolonged action potentials (APs) in congestive heart failure (CHF). A, Quantitative real‐time reverse transcription–polymerase chain reaction results for Kcna2 in heart samples from adult rats treated with various constructs (n=6). B and E, I Ks in cardiomyocytes isolated from adult rats treated with various constructs (n=6). Control indicates sham surgery; SE si RNA , knockdown of Kcna2 expression in healthy rat hearts; CHF + EGFP , enhanced green fluorescent protein ( EGFP ) expressing control in rat hearts with CHF ; CHF + SE , overexpression of Kcna2 in rat hearts with CHF ; CHF + SE si RNA , knockdown of Kcna2 in rat hearts with CHF . C and F, Representative traces of AP s in adult rat cardiomyocytes (n=6). D, Representative traces of calcium channel current density (n=6). Data are mean±SEM (B and E). APD indicates AP duration. * P <0.05 vs control, **** P <0.0001 vs control, # P <0.05 vs CHF, ## P <0.01 vs CHF .

Article Snippet: The following primary antibodies were used: anti‐rabbit Kcna2 (1:200; Alomone Labs), anti‐rabbit kvβ1 (1:1000; Abcam, Cambridge, UK), and anti‐GAPDH (1:1000; Cell Signaling Technology, Boston, MA) at 4°C overnight.

Techniques: Reverse Transcription, Polymerase Chain Reaction, Construct, Isolation, Control, Knockdown, Expressing, Over Expression

Journal: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Article Title: Long Noncoding RNA Kcna2 Antisense RNA Contributes to Ventricular Arrhythmias via Silencing Kcna2 in Rats With Congestive Heart Failure

doi: 10.1161/JAHA.117.005965

Figure Lengend Snippet: The role of Kcna2 in ventricular arrhythmias in congestive heart failure ( CHF ). A, Examples of norepinephrine‐induced arrhythmias in hearts from rats with CHF , and normal ECG s from control hearts (n=10). Arrhythmias included ventricular premature beat ( VPB ), ventricular tachycardia ( VT ), and ventricular fibrillation ( VF ). B, Data are expressed as the percentage incidence, and the actual incidence is indicated by the numbers above each bar. EGFP indicates enhanced green fluorescent protein; and SE, sense, Kcna2. * P <0.05 vs control, # P <0.05 vs CHF .

Article Snippet: The following primary antibodies were used: anti‐rabbit Kcna2 (1:200; Alomone Labs), anti‐rabbit kvβ1 (1:1000; Abcam, Cambridge, UK), and anti‐GAPDH (1:1000; Cell Signaling Technology, Boston, MA) at 4°C overnight.

Techniques: Control

Journal: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Article Title: Long Noncoding RNA Kcna2 Antisense RNA Contributes to Ventricular Arrhythmias via Silencing Kcna2 in Rats With Congestive Heart Failure

doi: 10.1161/JAHA.117.005965

Figure Lengend Snippet: Kcna2 antisense RNA (AS) controls slow component of the delayed rectifier potassium current (I Ks ) and action potentials ( AP s) in congestive heart failure ( CHF ). A, Quantitative real‐time reverse transcription–polymerase chain reaction (qRT‐ PCR ) results for Kcna2 AS in heart samples from adult rats treated with various constructs (n=6). I Ks (B) and AP (C) records from cardiomyocytes isolated from adult rats treated with various constructs (n=6). Control indicates sham surgery; CHF , rats with CHF; CHF + EGFP , enhanced green fluorescent protein (E GFP )–expressing control in rat hearts with CHF . D, qRT ‐ PCR results for Kcna2 AS in cultured cardiomyocytes treated with various constructs (n=6).I Ks (E) and AP (F) recordings from freshly isolated neonatal rat ventricular myocytes (n=6). Control indicates untreated group; phenylephrine, treated with 50 μmol/L phenylephrine; phenylephrine+ AS si RNA , transfection of adenovirus vector ( ADV) –Kcna2 AS ‐si RNA into phenylephrine‐treated cells; phenylephrine+ NC , transfection of ADV ‐ GFP into phenylephrine‐treated cells. Data are mean±SEM (B and C). APD indicates AP duration; and I end indicates the last 10ms of tail current. * P <0.05 vs control, ** P <0.01 vs CHF, *** P <0.01 vs phenylephrine, **** P <0.0001 vs control, # P <0.05 vs CHF.

Article Snippet: The following primary antibodies were used: anti‐rabbit Kcna2 (1:200; Alomone Labs), anti‐rabbit kvβ1 (1:1000; Abcam, Cambridge, UK), and anti‐GAPDH (1:1000; Cell Signaling Technology, Boston, MA) at 4°C overnight.

Techniques: Reverse Transcription, Polymerase Chain Reaction, Quantitative RT-PCR, Construct, Isolation, Control, Expressing, Cell Culture, Transfection, Plasmid Preparation

Journal: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Article Title: Long Noncoding RNA Kcna2 Antisense RNA Contributes to Ventricular Arrhythmias via Silencing Kcna2 in Rats With Congestive Heart Failure

doi: 10.1161/JAHA.117.005965

Figure Lengend Snippet: Kcna2 antisense RNA ( AS ) is arrhythmogenic in congestive heart failure (CHF). A, Examples of norepinephrine‐induced arrhythmias in hearts from rats with CHF and normal ECG s in control hearts (n=10). Arrhythmias included ventricular premature beats ( VPB s), ventricular tachycardia ( VT ), and ventricular fibrillation ( VF ). B, Data are expressed as the percentage incidence, and the actual incidence is indicated by the numbers above each bar. EGFP indicates enhanced green fluorescent protein. * P <0.05 vs control, # P <0.05 vs CHF .

Article Snippet: The following primary antibodies were used: anti‐rabbit Kcna2 (1:200; Alomone Labs), anti‐rabbit kvβ1 (1:1000; Abcam, Cambridge, UK), and anti‐GAPDH (1:1000; Cell Signaling Technology, Boston, MA) at 4°C overnight.

Techniques: Control

Journal: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Article Title: Long Noncoding RNA Kcna2 Antisense RNA Contributes to Ventricular Arrhythmias via Silencing Kcna2 in Rats With Congestive Heart Failure

doi: 10.1161/JAHA.117.005965

Figure Lengend Snippet: Kcna2 is a target gene of Kcna2 antisense RNA ( AS ). Western blot analysis for Kcna2 and Kvβ1 (A) and quantitative real‐time reverse transcription–polymerase chain reaction (qRT‐ PCR ) results for Kcna2 AS and the Kcna2 gene (C) in cultured cardiomyocytes treated with adenovirus vector ( ADV )–Kcna2 AS (n=6). Western blot analysis for Kcna2 and Kvβ1 (B) and qRT ‐ PCR results for Kcna2 AS and the Kcna2 gene (D) in cultured cardiomyocytes treated with ADV ‐Kcna2 AS ‐si RNA (n=6). E and F, Western blot and qRT ‐ PCR analysis for Kcna2 in heart samples from normal rats, rats with congestive heart failure (CHF), rats with CHF treated with adeno‐associated virus 9 ( AAV 9)–Kcna2 AS ‐si RNA , and normal rats treated with AAV 9‐Kcna2 AS (n=6). GFP indicates green fluorescent protein. * P <0.05 vs control, # P <0.05 vs CHF.

Article Snippet: The following primary antibodies were used: anti‐rabbit Kcna2 (1:200; Alomone Labs), anti‐rabbit kvβ1 (1:1000; Abcam, Cambridge, UK), and anti‐GAPDH (1:1000; Cell Signaling Technology, Boston, MA) at 4°C overnight.

Techniques: Western Blot, Reverse Transcription, Polymerase Chain Reaction, Quantitative RT-PCR, Cell Culture, Plasmid Preparation, Virus, Control